123 related articles for article (PubMed ID: 37880075)
1. Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World Study.
Kobat H; Elkonaissi I; Foreman E; Davidson M; Idaikkadar P; O'Brien M; Nabhani-Gebara S
Clin Lung Cancer; 2024 Jan; 25(1):e35-e42. PubMed ID: 37880075
[TBL] [Abstract][Full Text] [Related]
2. Investigating the efficacy of osimertinib and crizotinib in phase 3 clinical trials on anti-cancer treatment-induced cardiotoxicity: are real-world studies the way forward?
Kobat H; Elkonaissi I; Foreman E; O'Brien M; Dorak MT; Nabhani-Gebara S
J Oncol Pharm Pract; 2023 Apr; 29(3):646-662. PubMed ID: 35167392
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC.
Bishnoi R; Shah C; Blaes A; Bian J; Hong YR
Lung Cancer; 2020 Dec; 150():172-177. PubMed ID: 33186859
[TBL] [Abstract][Full Text] [Related]
4. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Baumann P; Langer CJ
Clin Lung Cancer; 2021 Jan; 22(1):49-57. PubMed ID: 33250347
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J
Front Immunol; 2022; 13():908173. PubMed ID: 35880172
[TBL] [Abstract][Full Text] [Related]
7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer.
Chitturi KR; Xu J; Araujo-Gutierrez R; Bhimaraj A; Guha A; Hussain I; Kassi M; Bernicker EH; Trachtenberg BH
JACC CardioOncol; 2019 Dec; 1(2):182-192. PubMed ID: 34396181
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis.
Chen X; Jiang A; Zhang R; Fu X; Liu N; Shi C; Wang J; Zheng X; Tian T; Liang X; Ruan Z; Yao Y
Front Cardiovasc Med; 2022; 9():882167. PubMed ID: 35669482
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.
Sun S; Liu C; Duan C; Yu S; Zhang Q; Xu N; Yu B; Wu X; Wang J; Hu X; Yu H
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2937-2949. PubMed ID: 35835883
[TBL] [Abstract][Full Text] [Related]
14. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.
Nakahama K; Izumi M; Yoshimoto N; Fukui M; Sugimoto A; Nagamine H; Ogawa K; Sawa K; Tani Y; Kaneda H; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
Anticancer Res; 2023 May; 43(5):2185-2197. PubMed ID: 37097681
[TBL] [Abstract][Full Text] [Related]
15. PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
Zhu Y; Zhang Y; Hu X; Wang M; Wang H; Liu Y
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3557-3566. PubMed ID: 35857126
[TBL] [Abstract][Full Text] [Related]
16. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
[TBL] [Abstract][Full Text] [Related]
17. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S; Shih JY; Jang TW; Liam CK; Yu Y
Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
[TBL] [Abstract][Full Text] [Related]
18. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non-Small Cell Lung Cancer in Taiwan.
Chang WT; Lin HW; Chang TC; Lin SH; Li YH
JAMA Netw Open; 2023 May; 6(5):e2313824. PubMed ID: 37195663
[TBL] [Abstract][Full Text] [Related]
20. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]